Zacks Research Has Bearish Estimate for JAZZ Q4 Earnings

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Investment analysts at Zacks Research cut their Q4 2025 earnings estimates for Jazz Pharmaceuticals in a research report issued on Monday, February 2nd. Zacks Research analyst Team now expects that the specialty pharmaceutical company will earn $5.15 per share for the quarter, down from their prior forecast of $5.16. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q2 2026 earnings at $4.88 EPS, Q3 2026 earnings at $5.25 EPS, Q4 2026 earnings at $5.00 EPS, Q2 2027 earnings at $5.04 EPS, Q3 2027 earnings at $5.70 EPS, Q4 2027 earnings at $5.50 EPS and FY2027 earnings at $20.06 EPS.

JAZZ has been the topic of a number of other research reports. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. Needham & Company LLC increased their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. UBS Group reissued a “neutral” rating and issued a $188.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Finally, Wells Fargo & Company boosted their price target on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Fourteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $205.67.

Jazz Pharmaceuticals Trading Down 1.6%

Shares of NASDAQ:JAZZ opened at $163.15 on Wednesday. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $182.99. The stock’s fifty day moving average price is $168.08 and its 200-day moving average price is $144.95. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The company has a market cap of $9.91 billion, a P/E ratio of -26.88, a PEG ratio of 0.89 and a beta of 0.26.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Cardinal Capital Management boosted its stake in Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after buying an additional 66 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 9.0% in the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 81 shares in the last quarter. Tectonic Advisors LLC increased its position in Jazz Pharmaceuticals by 1.5% in the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after purchasing an additional 82 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 83 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its position in Jazz Pharmaceuticals by 0.6% during the second quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock valued at $1,651,000 after purchasing an additional 90 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total transaction of $379,363.38. Following the transaction, the senior vice president owned 19,508 shares in the company, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the transaction, the director owned 393,332 shares in the company, valued at $69,938,362.92. The trade was a 16.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 123,791 shares of company stock worth $21,991,850. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks raised its FY2027 EPS view to $20.06 (from $19.95) and bumped several 2026–2027 quarterly estimates (Q4 2027 to $5.50, Q3 2027 to $5.70, Q2 2027 to $5.04, Q4 2026 to $5.00). Those upward revisions signal improving medium-term profit expectations from a well-known independent research shop, which can support higher valuation expectations. Zacks Research Issues Positive Outlook for JAZZ Earnings
• Neutral Sentiment: The estimate changes are mostly small in magnitude (cent-to-tenth-of-dollar moves), suggesting incremental rather than transformational upside; investors may wait for company-reported results to confirm the trend before materially re-pricing the stock.
• Negative Sentiment: Zacks trimmed a few nearer-term quarter estimates (Q2 2026 to $4.88, Q3 2026 to $5.25, Q4 2025 to $5.15). Even modest downgrades to near-term prints can prompt short-term selling or raise caution among traders focused on the next reported quarter.
• Negative Sentiment: Despite the mostly positive medium-term lift, the stock traded lower — likely reflecting profit-taking/technical pressure after a recent run toward its 52-week high and the 50-day moving average acting as resistance (50‑day MA $168.36 vs. current below that). Lower-than-average intraday volume also suggests limited buying conviction.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.